Supporting Information

Radionuclide I-131 Labeled Albumin-Paclitaxel Nanoparticles for Synergistic Combined Chemo-radioisotope Therapy of Cancer

Longlong Tian[1,2‡], Qian Chen[2‡], Xuan Yi[1], Guanglin Wang[1], Jie Chen[1], Ping Ning[1], Kai Yang[1*✉], Zhuang Liu[2*✉]

1. School of Radiation Medicine and Protection & School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, Jiangsu, 215123, China
2. Institute of Functional Nano & Soft Materials (FUNSOM), Collaborative Innovation Center of Suzhou Nano Science and Technology, Soochow University, Suzhou, Jiangsu, 215123, China

✉Corresponding authors: kyang@suda.edu.cn, zliu@suda.edu.cn
‡These authors contributed equally to this work



Supporting information Figure S1. The biodistribution of ^{131}I-HSA-PTX nanoparticles at 24, 48 and 72 h determined by a gamma counter to measure radioactivity levels in different organs.